The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

We reviewed the biological pathways involved in Malignant pleural mesothelioma, the clinical trials about targeted therapy, and possible related mechanisms of resistance

Giuseppe Bronte

2016

Scholarcy highlights

  • Malignant pleural mesothelioma is an aggressive tumor of the pleura with a poor prognosis
  • Advances in the understanding of tumor molecular biology have led to the development of several targeted treatments, which have been evaluated in clinical trials
  • None of the explored targeted treatments can currently be recommended as routine treatment in MPM
  • We reviewed the biological pathways involved in MPM, the clinical trials about targeted therapy, and possible related mechanisms of resistance
  • We suggest that specific genetic markers are needed as targets of selective therapy
  • By this way the selection of patients based on the molecular profile may facilitate a therapeutic strategy that allows the use of the most appropriate drug for each patient

Need more features? Save interactive summary cards to your Scholarcy Library.